Literature DB >> 23466651

Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.

Ziyan Lu1, Yufeng Tian, Helen R Salwen, Alexandre Chlenski, Lucy A Godley, J Usha Raj, Qiwei Yang.   

Abstract

Neuroblastoma (NB), a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behaviors ranging from spontaneous remission to rapid tumor progression and death. In addition to genetic abnormalities, recent studies have indicated that epigenetic aberrations also contribute toward NB pathogenesis. However, the epigenetic mechanisms underlying the pathogenesis of NB are largely unknown. Inhibition of euchromatic histone-lysine N-methyltransferase 2 (EHMT2) was evaluated through the measurement of H3K9Me2 levels. Cell proliferation was examined by cell counting in human NB cell lines (LA1-55n, IMR-5, and NMB). The RNA expression of EHMT2, MYCN, and p21 was measured by real-time PCR. The expression of PCNA, MYCN, p53, cyclinD1, H3, H3K27M2, and H3K9Me2 was examined by western blot analysis. In-vitro invasion and the effects of the EHMT2 inhibitor (BIX-01294) were assessed in the Transwell chamber assay. Caspase 3 and 8 activities were measured using a Caspase-Glo assay kit. The level of overall DNA methylation was measured by liquid chromatography-mass spectroscopy. BIX-01294, a specific inhibitor of EHMT2 (a key enzyme for histone H3 dimethylation at lysine-9), specifically decreases the overall H3K9Me2 level but not H3K27Me2. The inhibition of EHMT2 decreased the proliferation of NB cells and induced apoptosis by increasing caspase 8/caspase 3 activity. BIX-01294 inhibited NB cell mobility and invasion. This was accompanied by a decreased expression of the MYCN oncogene. Inhibition of EHMT2 enhanced a doxorubicin-induced inhibitory effect on cell proliferation. Finally, EHMT2 inhibition modulated overall DNA methylation levels in NB cells. Our results show that histone-lysine methylation is involved in cell proliferation, apoptosis, cell invasion, and overall DNA methylation in human NB cells. Further understanding of this mechanism may provide an insight into the pathogenesis of NB progression and lead to novel treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23466651      PMCID: PMC3649845          DOI: 10.1097/CAD.0b013e32835ffdbb

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  35 in total

1.  Role of histone H3 lysine 27 methylation in Polycomb-group silencing.

Authors:  Ru Cao; Liangjun Wang; Hengbin Wang; Li Xia; Hediye Erdjument-Bromage; Paul Tempst; Richard S Jones; Yi Zhang
Journal:  Science       Date:  2002-09-26       Impact factor: 47.728

2.  EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.

Authors:  Chunxi Wang; Zhihui Liu; Chan-Wook Woo; Zhijie Li; Lifeng Wang; Jun S Wei; Victor E Marquez; Susan E Bates; Qihuang Jin; Javed Khan; Kai Ge; Carol J Thiele
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

3.  Doxorubicin-induced apoptosis in caspase-8-deficient neuroblastoma cells is mediated through direct action on mitochondria.

Authors:  A Rebbaa; P M Chou; M Emran; B L Mirkin
Journal:  Cancer Chemother Pharmacol       Date:  2001-12       Impact factor: 3.333

4.  Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells.

Authors:  C Friesen; S Fulda; K M Debatin
Journal:  Cell Death Differ       Date:  1999-05       Impact factor: 15.828

5.  Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.

Authors:  Qiwei Yang; Peter Zage; David Kagan; Yufeng Tian; Roopa Seshadri; Helen R Salwen; Shuqing Liu; Alexandre Chlenski; Susan L Cohn
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

6.  Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.

Authors:  Qi-Wei Yang; Shuqing Liu; Yufeng Tian; Helen R Salwen; Alexandre Chlenski; Joanna Weinstein; Susan L Cohn
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

7.  Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells.

Authors:  Sally Hopkins-Donaldson; Pu Yan; Katia Balmas Bourloud; Annick Muhlethaler; Jean-Luc Bodmer; Nicole Gross
Journal:  Oncogene       Date:  2002-09-05       Impact factor: 9.867

8.  Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line.

Authors:  J Foley; S L Cohn; H R Salwen; D Chagnovich; J Cowan; K L Mason; L M Parysek
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

9.  Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.

Authors:  S L Cohn; H Salwen; M W Quasney; N Ikegaki; J M Cowan; C V Herst; R H Kennett; S T Rosen; J A DiGiuseppe; G M Brodeur
Journal:  Oncogene       Date:  1990-12       Impact factor: 9.867

10.  Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma.

Authors:  Qiwei Yang; Shuqing Liu; Yufeng Tian; Chiler Hasan; Donna Kersey; Helen R Salwen; Alexandre Chlenski; Elizabeth J Perlman; Susan L Cohn
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

View more
  25 in total

1.  Status of epigenetic chromatin modification enzymes and esophageal squamous cell carcinoma risk in northeast Indian population.

Authors:  Virendra Singh; Laishram C Singh; Avninder P Singh; Jagannath Sharma; Bibhuti B Borthakur; Arundhati Debnath; Avdhesh K Rai; Rup K Phukan; Jagadish Mahanta; Amal C Kataki; Sujala Kapur; Sunita Saxena
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 2.  Epigenetics in NG2 glia cells.

Authors:  Sarah Moyon; Jialiang Liang; Patrizia Casaccia
Journal:  Brain Res       Date:  2015-06-17       Impact factor: 3.252

3.  [Methyltransferase inhibitor BIX01294 promotes the migration and inhibits decidualization of mouse uterine stromal cells in vitro].

Authors:  Hui-Qi Liao; Liu Tian; Hui Yang; Ni Ma; Chang-Jun Zhang; Hong-Lu Diao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-06-20

Review 4.  Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.

Authors:  David F Tough; Huw D Lewis; Inmaculada Rioja; Matthew J Lindon; Rab K Prinjha
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

Review 5.  Role of epigenetic modifications in luminal breast cancer.

Authors:  Hany A Abdel-Hafiz; Kathryn B Horwitz
Journal:  Epigenomics       Date:  2015-02-17       Impact factor: 4.778

6.  The role of DNA methylation and histone modifications in blood pressure: a systematic review.

Authors:  Valentina Gonzalez-Jaramillo; Eliana Portilla-Fernandez; Marija Glisic; Trudy Voortman; Wichor Bramer; Rajiv Chowdhury; Anton J M Roks; A H Jan Danser; Taulant Muka; Jana Nano; Oscar H Franco
Journal:  J Hum Hypertens       Date:  2019-07-25       Impact factor: 3.012

Review 7.  Targeting the histone orthography of cancer: drugs for writers, erasers and readers.

Authors:  Laia Simó-Riudalbas; Manel Esteller
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 8.  Targeting epigenetic regulations in cancer.

Authors:  Bo Ning; Wenyuan Li; Wei Zhao; Rongfu Wang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-10-26       Impact factor: 3.848

9.  EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells.

Authors:  Jing Cui; Wendong Sun; Xuexi Hao; Minli Wei; Xiaonan Su; Yajing Zhang; Ling Su; Xiangguo Liu
Journal:  Cancer Cell Int       Date:  2015-02-04       Impact factor: 5.722

Review 10.  Molecular targeting therapies for neuroblastoma: Progress and challenges.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Xinjie Wang; Wa Xian; Frank McKeon; Jennifer Foster; Jia Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2020-11-06       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.